Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
Clinical trial NCT05889351 · COMPLETED
Trial details
- NCT number
- NCT05889351
- Sponsor
- Pharma Holdings AS
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-19
- Primary completion
- 2022-10-28
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.